Study of A-101 Topical Solution for the Treatment of Common Warts



Status:Recruiting
Conditions:Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:2 - Any
Updated:3/28/2019
Start Date:September 17, 2018
End Date:August 30, 2019
Contact:Judy Schynder
Email:jschnyder@aclaristx.com
Phone:484-329-2144

Use our guide to learn which trials are right for you!

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts

A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical
Solution Applied Twice a Week in Subjects with Common Warts

Inclusion Criteria:

1. Subject or legal guardian is able to comprehend and is willing to sign an informed
consent/assent for participation in this study.

2. Male or female ≥ 1 years old.

3. Subject has a clinical diagnosis of common warts (verruca vulgaris).

4. Subject has at least 1 and up to 6 clearly identifiable common warts located on the
trunk or extremities that meet the requirements as defined below:

1. Have a longest axis that is ≥3 and ≤8 mm and have a thickness of ≤3mm

2. Be a discrete lesion, i.e. each wart meeting the entry criteria is clearly
separated from other warts.

3. Be present for at least 4 weeks

4. Not be covered with hair which, in the investigator's opinion, would interfere
with the study medication treatment or the study evaluations

5. Not be in an intertriginous fold

6. Periungual, subungual, genital, anal, mosaic, plantar, flat and filiform warts
are excluded from treatment and evaluation. If a subject has these types of
warts, but also has warts that meet the inclusion criteria, the subject will NOT
be excluded from the study.

5. Each common wart identified for treatment must have a PWA ≥ 2.

6. Subject's chemistry and complete blood count results are within normal limits.

7. Subject is in good general health and free of any known disease state or physical
condition.

8. Subject is willing and able to follow all study instructions and to attend all study
visits.

9. Subject must be the only individual in a household participating in the study.

Exclusion Criteria:

1. Subject has clinically atypical warts.

2. Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic
immunodeficiency, transplant status, etc.).

3. Subject has a history of Human Immunodeficiency Virus (HIV) infection.

4. Subject has had any Human Papilloma Virus (HPV) vaccine within 6 months prior to Visit
1.

5. Subject has used any of the following intralesional therapies within the specified
period prior to Visit 2:

- Immunotherapy (e.g., Candida antigen, mumps antigen, Trichophyton antigen); 8
weeks

- Anti-metabolite therapy (e.g., bleomycin, 5-fluorouracil); 8 weeks

6. Subject has used any of the following systemic therapies within the specified period
prior to Visit 2:

- Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept,
infliximab); 16 weeks

- Glucocorticosteroids (inhaled and intra-nasal steroids are permitted); 28 days

7. Subject has used any of the following topical therapies within the specified period
prior to Visit 2 on, or in the proximity to any of the common warts identified for
treatment, that in the investigator's opinion interferes with the study medication
treatment or the study assessments:

- LASER, light or other energy-based therapy (e.g., intense pulsed light [IPL],
photodynamic therapy [PDT]); 180 days

- Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester[SADBE], etc.) 12 weeks

- Liquid nitrogen, electrodesiccation, curettage; 60 days

- Hydrogen peroxide; 90 days

- Antimetabolite therapy (e.g., 5-fluorouracil); 8 weeks

- Retinoids; 90 days

- Over-the-counter (OTC) wart therapies and cantharidin; 28 days

8. Subject currently has or has had any of the following within the specified period
prior to Visit 1 on or in the proximity to any of the common warts identified for
treatment that, in the investigator's opinion, interferes with the study medication
treatment or the study assessments:

- Cutaneous malignancy; 180 days

- Sunburn; currently

- Pre-malignancy (e.g., actinic keratosis); currently

9. Subject has a history of sensitivity to any of the ingredients in the study
medications.

10. Subject has any current skin or systemic disease (e.g., psoriasis, atopic dermatitis,
eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that,
in the opinion of the investigator, might put the subject at undue risk by study
participation or interfere with the study conduct or evaluations.

11. Participation in another therapeutic investigational drug/device trial in which
administration of an investigational treatment occurred with 30 days prior to Visit 1.

12. Subject has an active malignancy.

13. Subjects is viewed by the Principal Investigator as not being able to complete the
study.
We found this trial at
24
sites
Indianapolis, Indiana 46256
Phone: 484-329-2144
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Austin, Texas 78759
Phone: 484-329-2144
?
mi
from
Austin, TX
Click here to add this to my saved trials
Aventura, Florida 33180
Phone: 484-329-2144
?
mi
from
Aventura, FL
Click here to add this to my saved trials
Broomall, Pennsylvania 19008
Phone: 484-329-2144
?
mi
from
Broomall, PA
Click here to add this to my saved trials
Charleston, South Carolina 29407
Phone: 484-329-2144
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chestnut Hill, Massachusetts 02467
Phone: 484-329-2144
?
mi
from
Chestnut Hill, MA
Click here to add this to my saved trials
Fort Washington, Pennsylvania 19034
Phone: 484-329-2144
?
mi
from
Fort Washington, PA
Click here to add this to my saved trials
Fountain Valley, California 92708
Phone: 484-329-2144
?
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Fridley, Minnesota 55432
Phone: 484-329-2144
?
mi
from
Fridley, MN
Click here to add this to my saved trials
Greenville, South Carolina 29607
Phone: 484-329-2144
?
mi
from
Greenville, SC
Click here to add this to my saved trials
Hot Springs, Arkansas 71913
Phone: 484-329-2144
?
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Jacksonville, Florida 32256
Phone: 484-329-2144
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Las Vegas, Nevada 89148
Phone: 484-329-2144
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Louisville, Kentucky 40241
Phone: 484-329-2144
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Miami, Florida 33137
Phone: 484-329-2144
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mobile, Alabama 36608
Phone: 484-329-2144
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Newnan, Georgia 30263
Phone: 484-329-2144
?
mi
from
Newnan, GA
Click here to add this to my saved trials
Ocala, Florida 34470
Phone: 484-329-2144
?
mi
from
Ocala, FL
Click here to add this to my saved trials
Pflugerville, Texas 78660
Phone: 484-329-2144
?
mi
from
Pflugerville, TX
Click here to add this to my saved trials
San Antonio, Texas 78213
Phone: 484-329-2144
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Diego, California 92103
Phone: 484-329-2144
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Spokane, Washington 99202
Phone: 484-329-2144
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Verona, New Jersey 07044
Phone: 484-329-2144
?
mi
from
Verona, NJ
Click here to add this to my saved trials
Warren, Michigan 48088
Phone: 484-329-2144
?
mi
from
Warren, MI
Click here to add this to my saved trials